Table 3 Outcomes and subgroup analysis
From: Homeopathic drug proving of Okoubaka aubrevillei: a randomised placebo-controlled trial
Placebo | Okoubaka aubrevillei | ||||
|---|---|---|---|---|---|
n | Characteristic symptoms | n | Characteristic symptoms | Significance of group difference, adjusted (P value) | |
Outcome | |||||
Characteristic symptoms | 11 | 4.9 (± 5.6) | 18 | 5.4 (± 6.0) | 0.843 |
Proving symptoms | 11 | 9.6 (± 10.6) | 18 | 8.8 (± 9.6) | 0.951 |
Subgroup analysis | |||||
Gender | |||||
Male | 3 | 2.3 (± 3.2) | 7 | 2.3 (± 2.8) | |
Female | 8 | 5.9 (± 6.2) | 11 | 7.5 (± 6.7) | |
Age | |||||
<35 years | 3 | 4.7 (± 5.6) | 13 | 5.2 (± 5.5) | |
≥35 years | 7 | 4.4 (± 6.2) | 5 | 6.2 (± 7.6) | |
Sensitivity (subjects’ estimation)a | |||||
- Strong reaction / reaction | 11 | 4.9 (± 5.6) | 10 | 5.8 (± 6.7) | |
- Slight reaction / no reaction | 0 | 0 | 7 | 4.7 (± 5.7) | |
Sensitivity (investigators’ estimation) | |||||
- Strong reaction / reaction | 10 | 5.4 (± 5.7) | 15 | 6.3 (± 6.2) | |
- Slight reaction / no reaction | 1 | 0 | 2 | 1.0 (± 1.4) | |
Expected reaction to homeopathic drug (subjects’ estimation) | |||||
- Very high number / many symptoms | 4 | 8.0 (± 7.0) | 2 | 1.5 (± 2.1) | |
- Low number / no symptoms | 7 | 3.1 (± 4.2) | 15 | 5.9 (± 6.3) | |
Expected reaction to homeopathic drug (investigators’ estimation) | |||||
- Very high number / many symptoms | 9 | 6.0 (± 5.7) | 10 | 7.5 (± 6.1) | |
- Low number / no symptoms | 2 | 0 | 7 | 3.0 (± 5.4) | |